Home › All Companies › XBIO › Insider Trading

Xenetic Biosciences, Inc. (XBIO) — Insider Trading

AI-Powered SEC Filing Analysis

← All XBIO filings
Latest Insider Trading Filed: 2026-04-23

Key Insights

  • James Parslow, serving as Interim CEO and CFO, received a restricted stock grant of 100,000 shares at no cost on April 21, 2026, with a staggered vesting schedule: 7,000 shares immediately and 31,000 shares annually over three years, indicating company commitment to retaining interim leadership.
  • The grant was executed under a Rule 10b5-1 trading plan, suggesting this compensation was pre-arranged and not a reactive response to market conditions, which provides greater transparency regarding executive compensation practices.
  • The zero-dollar price for the RSG indicates this is a non-cash equity award rather than a market purchase, representing potential dilution to existing shareholders while aligning the interim CEO's interests with long-term company performance through multi-year vesting.
Sentiment: Neutral Significance: 4/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-04-23. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Xenetic Biosciences, Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.